Will receive a breast cancer diagnosis in their lifetime.
And BCAL intends to detect her.
Who we are
BCAL Diagnostics, an Australian and US-based biotechnology company, is committed to improving breast cancer outcomes through early, accurate diagnosis. For over a decade, we’ve been developing non-invasive, highly accessible technologies to aid in breast cancer detection.
We invite you to learn more about us and our mission-critical goal to enhance early detection and improve breast cancer screening effectiveness and outcomes for women.
Jayne Shaw Co-Founder and Executive Chair, Dr John Hurrell Non-Executive Director and Consultant, Shane Ryan Chief Executive Officer
What we do
BCAL Diagnostics is an emerging leader in early breast cancer diagnosis, developing non-invasive tools to complement existing imaging technologies.
Initially designed to complement mammograms, our innovative tools aim to evolve into a comprehensive screening and monitoring solution for women of all ages and backgrounds, worldwide
We strive to provide reliable results that integrate seamlessly with other screening methods, empowering healthcare professionals to improve outcomes for breast cancer patients.
BCAL Diagnostics has been developing a non-invasive diagnostic tool over the past decade, which is designed to benefit women of all ages and backgrounds, enhancing outcomes through assisting in timely intervention and advanced screening.
An effective and accurate blood test should increase the screening detection rate and reduce mortality. A lipidomic signature from plasma used to detect localized breast cancer would be clinically valuable.
